Purinomia Biotech

Purinomia Biotech is a clinical-stage company focused on developing innovative therapeutics for cancer and inflammatory diseases. They focus on the role of purine nucleotides and their receptors (purinergic receptors) in cellular communication and disease processes in order to design and develop small molecule drugs that specifically target these validated purinergic signaling pathways. They are developing therapies targeting specific vulnerabilities in cancer cells related to purine metabolism to disrupt the cancer cell's ability to grow and survive. Their research also focuses on the role of purinergic signaling pathways in inflammation to treat conditions like rheumatoid arthritis and inflammatory bowel disease. Their lead compound, PUR001, is a small molecule inhibitor targeting a specific purinergic signaling pathway for the treatment of various solid tumors. It is in clinical stages. Purinomia has additional pre-clinical programs at various stages of development

Jobs: